Andtbacka, R. H., Collichio, F. A., Amatruda, T., Senzer, N., Chesney, J., Delman, K., . . . Kaufman, H. (2014). Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704). J Immunother Cancer.
Citação norma ChicagoAndtbacka, Robert HI, et al. "Final Planned Overall Survival (OS) From OPTiM, a Randomized Phase III Trial of Talimogene Laherparepvec (T-VEC) Versus GM-CSF for the Treatment of Unresected Stage IIIB/C/IV Melanoma (NCT00769704)." J Immunother Cancer 2014.
Citação norma MLAAndtbacka, Robert HI, et al. "Final Planned Overall Survival (OS) From OPTiM, a Randomized Phase III Trial of Talimogene Laherparepvec (T-VEC) Versus GM-CSF for the Treatment of Unresected Stage IIIB/C/IV Melanoma (NCT00769704)." J Immunother Cancer 2014.